Mechanisms of an education intervention to remediate cognitive dysfunction associated with cancer and its treatment

Not Applicable

Completed

• Conditions: Cancer - Any cancer; Cancer-related cognitive dysfunction; Mental Health - Other mental health disorders

• Registration Number: ACTRN12615000009516
• Lead Sponsor: Griffith University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-01-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

18 years or more; experienced adult-onset cancer (excluding cancer known to have affected the central nervous system); completed all major treatments for cancer (such as surgery, chemotherapy, and radiotherapy) at least 6 months prior to data collection (but ongoing hormone treatments were acceptable, e.g. oestrogen modifiers or androgen-suppressing medications); subjective cognitive impairment as shown by a score of <100 on the EORTC-QLQ-C30 cognitive function subscale. Healthy volunteers were required to be 18 years or over and have never been diagnosed with cancer.

Exclusion Criteria

Cancer known to involve the central nervous system (primary or secondary tumours). Previous treatment with cranial radiotherapy or intrathecal chemotherapy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Subjective cognitive function, as assessed by the Functional Assessment of Cancer Therapy Cognitive Function 3 (FACT-Cog-3) and the Brief Assessment of Prospective Memory[Baseline, post-intervention (6 weeks after baseline) and follow-up (3 months after intervention completion)];Objective cognitive function, as assessed by the Repeatable Battery for Assessment of Neuropsychological Status (RBANS) and the Trailmaking Test[Baseline, Post-intervention (6 weeks after baseline), and Follow-up (3 months after intervention)]

Secondary Outcome Measures

Name	Time	Method
Distress, as assessed by the Kessler Psychological Distress scale (K10)[Baseline, post-intervention (6 weeks after baseline) and follow-up (3 months after intervention completion)];Quality of life, as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire version 3 (EORTC-QLQ-C30)[Baseline, post-intervention (6 weeks after baseline) and follow-up (3 months after intervention completion)];Illness perceptions, as assessed by the Brief Illness Perceptions Questionnaire[Baseline, post-intervention (6 weeks after baseline) and follow-up (3 months after intervention completion)];Cognitive Self-Efficacy, as assessed by the Cognitive Self-Efficacy Scale[Baseline, post-intervention (6 weeks after baseline) and follow-up (3 months after intervention completion)];Benefit finding, as assessed by the Benefit Finding Scale[Baseline, post-intervention (6 weeks after baseline) and follow-up (3 months after intervention completion)]